Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Predicting Treatment Response to Memantine in Autism Spectrum Disorder Using MR Spectroscopy

NCT02811627 is registered in ClinicalTrials.gov with University of Missouri-Columbia as lead sponsor.

NCT NCT02811627
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT02811627 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Predicting Treatment Response to Memantine in Autism Spectrum Disorder Using MR Spectroscopy
Lead sponsor
University of Missouri-Columbia
Phase
Phase 1
Overall status
Completed
Start date
June 30, 2016
Completion date
April 30, 2021
Enrollment
10 (actual)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

autism spectrum disorder